Research programme: skin disorder therapeutics - Kythera
Latest Information Update: 14 Oct 2015
At a glance
- Originator Kythera Biopharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Skin disorders
Most Recent Events
- 01 Oct 2015 Kythera Biopharmaceuticals has been acquired by Allergan
- 15 Jul 2015 Development is ongoing in USA
- 21 Jul 2010 Early research in Skin disorders in USA (topical; unspecified route)